Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

In a report published Monday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros Corporation (NASDAQ: OMER ). In the report, Wedbush noted, “A recent conversation with a high-volume cataract surgeon on OMS302's potential use enhances our outlook for Omeros. The FDA is cracking down on sterility of topical